The global GLP-1 analogues market is projected to reach USD 471.10 billion by 2032 from USD 47.49 billion in 2024, at a CAGR of 33.2% during the forecast period. The growth of this market is majorly driven by the presence of a robust R&D pipeline, improved efficacy offered by GLP-1 drugs, and the high demand from end users. On the other hand, high entry barriers to new entrants due to the current duopoly restrain the growth of this market.
The GLP-1 analogues market is segmented by product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Xultophy, Soliqua, Zepbound, Bydureon, and other products. Ozempic accounted for the largest market owing to its high adoption and established brand recognition. Zepbound held the fastest growth rate of 50.3% during the forecast period due to rapid growth in adoption, growing focus on anti-obesity medicines (AOMS), and anticipated regulatory approvals across different geographies.
Based on the format, the GLP-1 analogues market is segmented into single-dose, multi-dose, and tablet formats. The single-dose format held the largest share (84.1%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 413.34 billion by 2032 from USD 40.10 billion in 2024, at a CAGR of 33.9% during the forecast period. The major factors driving the growth of this segment are the ease of administration, the growing availability of single dose autoinjectors, and the lower injection frequency.
Based on the route of administration, the GLP-1 analogues market is segmented into subcutaneous and oral administration. Subcutaneous administration is further segmented based on injector type into pen and autoinjectors. The subcutaneous route held the largest share (92.7%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 453.72 billion by 2032 from USD 44.21 billion in 2024, at a CAGR of 33.8% during the forecast period. The major factors driving the growth of this segment are the presence of many marketed products administered subcutaneously, bypassing gastrointestinal tract-associated adverse effects, and faster onset of therapeutic action, among others.
Based on the indication, the GLP-1 analogues market is segmented into diabetes, obesity, and other indications. Diabetes held the largest share of the GLP-1 analogues market in 2023. This segment is projected to reach USD 338.84 billion by 2032 from USD 37.93 billion in 2024, at a CAGR of 31.5% during the forecast period. The major factors driving the growth of this segment are the high demand for GLP-1 drugs for type 2 diabetes, the strong pipeline, and the advantages of GLP-1 analogues over other antidiabetic drugs.
Based on end users, the global GLP-1 analogues market is segmented into home care settings, long-term care facilities, and hospitals & specialty clinics. The home care settings segment held the largest share (60.0%) of the GLP-1 analogues market in 2023. This segment is projected to reach USD 290.60 billion by 2032 from USD 28.58 billion in 2024, at a CAGR of 33.6% during the forecast period. The major factors driving the growth of this segment are ease and convenience of administration, leading to higher adherence.
ECOSYSTEM ANALYSIS
The GLP-1 analogues market ecosystem comprises raw material suppliers providing essential components like consumables and instrument manufacturers offering media, reagents, and end users such as hospitals & specialty clinics, long-term care facilities, and home care settings. Manufacturers develop and distribute GLP-1 analogues while navigating regulations set by bodies like the FDA and EMA, ensuring quality and compliance throughout the supply chain. This intricate network facilitates the production, research, and development of biopharmaceuticals and enables advancements in novel antidiabetics and weight management drugs.
GLP-1 ANALOGUES MARKET: ECOSYSTEM ANALYSIS
REGULATORY LANDSCAPE
The regulatory landscape for the GLP-1 analogues market is characterized by stringent guidelines and oversights to ensure the safety, efficacy, and quality of GLP-1 receptor agonists for indications such as diabetes and obesity. Regulatory bodies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional agencies are important in setting guidelines and requirements for developing, manufacturing, and commercializing GLP-1 analogues. The GLP-1 receptor agonists (GLP-1 RAs) are primarily approved for treating type 2 diabetes mellitus and obesity. GLP-1 receptor agonists mimic the action of the endogenous hormone GLP-1, which regulates insulin secretion from pancreatic B-cells. This is crucial for maintaining glucose homeostasis in patients with type 2 diabetes mellitus. As the market for GLP-1 drugs is predominantly concentrated in the US and Europe, the key regulatory authorities reviewing pipeline product trials are the US FDA and the European Medicines Agency (EMA). The US FDA has published a document named ‘Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention,’ which provides comprehensive recommendations for developing new drugs and biologics to treat and prevent diabetes mellitus. The document emphasizes factors such as efficacy endpoints, patient populations to be considered, and safety assessment considerations, among others.
